Evox Therapeutics advances MSH3 Huntington’s disease programme through eXmoor Pharma transfer
eXmoor Pharma and Evox complete an exosome gene-editing transfer, advancing the CMC path for Evox’s Huntington’s disease programme.
Pharma & Biotech
Pharma & Biotech
Why Thermo Fisher’s new Gothenburg lab matters for the next phase of complex drug development
Complex therapies need deeper trial data. Thermo Fisher’s Gothenburg lab shows why bioanalysis is becoming a CRO battleground.
Pharma & Biotech
How Andelyn Biosciences is targeting GMP scale-up challenges in lentiviral vector manufacturing
Cell therapy needs lentiviral vectors, but GMP scale-up remains messy. Andelyn Biosciences is betting standardization can close that gap.
Pharma & Biotech
What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.
Pharma & Biotech
What AGC Biologics’ role in Waskyra tells us about the future of ethical cell therapy scale-up
Waskyra’s FDA and EMA approvals spotlight AGC Biologics’ rare disease manufacturing model. Find out what this means for future nonprofit-led therapies.